Nuvalent (NUVL) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-280.4M
Net Income
-260.8M
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
72.0M
Shareholders Equity
1.1B
Debt to Equity
0.07
Cash Flow Metrics
Operating Cash Flow
-204.4M
Free Cash Flow
-185.1M
Revenue & Profitability Trend
Nuvalent Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 280.4M | 149.5M | 86.1M | 45.8M | 16.9M |
| Operating Income | -280.4M | -149.5M | -86.1M | -45.8M | -16.9M |
| Pre-tax Income | -260.0M | -126.2M | -81.9M | -46.3M | -14.6M |
| Income Tax | 764.0K | - | - | - | - |
| Net Income | -260.8M | -126.2M | -81.9M | -46.3M | -14.6M |
| EPS (Diluted) | - | -$2.17 | -$1.65 | -$2.13 | -$0.64 |
Income Statement Trend
Nuvalent Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.1B | 726.5M | 478.0M | 290.6M | 10.6M |
| Non-Current Assets | 9.3M | 5.9M | 4.5M | 3.2M | 0 |
| Total Assets | 1.1B | 732.4M | 482.5M | 293.8M | 10.6M |
| Liabilities | |||||
| Current Liabilities | 54.0M | 31.8M | 19.5M | 8.8M | 4.4M |
| Non-Current Liabilities | 17.9M | 0 | 0 | 0 | 37.6M |
| Total Liabilities | 72.0M | 31.8M | 19.5M | 8.8M | 42.0M |
| Equity | |||||
| Total Shareholders Equity | 1.1B | 700.6M | 463.0M | 285.0M | -31.3M |
Balance Sheet Composition
Nuvalent Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -260.8M | -126.2M | -81.9M | -46.3M | -14.6M |
| Operating Cash Flow | -204.4M | -99.9M | -68.6M | -43.7M | -15.7M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | -573.5M | -143.5M | -10.7M | -220.0M | 0 |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 568.9M | 322.7M | 247.1M | 318.2M | 22.2M |
| Free Cash Flow | -185.1M | -99.7M | -65.0M | -40.0M | -14.9M |
Cash Flow Trend
Nuvalent Key Financial Ratios
Valuation Ratios
Forward P/E
-17.92
Price to Book
5.39
PEG Ratio
-17.92
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-35.69%
Return on Assets
-22.23%
Financial Health
Current Ratio
14.48
Debt to Equity
0.00
Beta
1.34
Per Share Data
EPS (TTM)
-$4.42
Book Value per Share
$14.09
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| nuvl | 5.5B | - | 5.39 | -35.69% | 0.00% | 0.00 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.